Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The increase in Web production, system development and video production projects in the non-pharmaceutical EVC area, a large-scale streaming system project in the OTT area, and higher sales at consolidated subsidiaries contributed to revenue growth. The increase in expenses was contained through restrained hiring, cost reductions and more efficient organisational management. In the pharmaceutical EVC area, the lecture and seminar business fell below the previous year, mainly because major clients restrained budget spending.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥6,081 million (YoY +6.5%) |
| Operating profit | ¥414 million (YoY +14.5%) |
| Ordinary income | ¥438 million (YoY +14.2%) |
| Profit attributable to owners of the parent | ¥237 million (YoY +17.1%) |
| Net income per share | ¥9.56 |
| Equity ratio | End of the current fiscal period 80.5% / End of previous period 81.5% |
| Total assets | ¥13,161 million |
| Net assets | ¥11,080 million |
| Cash flows from operating activities | ¥937 million |
| Cash flows from investing activities | ¥-283 million |
| Cash flows from financing activities | ¥-395 million |
| Cash and cash equivalents at end of period | ¥8,032 million |
| Full-year earnings forecast | Net Sales ¥12,702 million (YoY +5.9%) / Operating profit ¥920 million (YoY +11.4%) / Ordinary income ¥950 million (YoY +9.7%) / Net income ¥536 million (YoY +10.6%) |
| Revision to Earnings Forecast | No (unchanged) |
| Annual Dividend Forecast | 14 Yen → 14 Yen（0.0%） |
| Depreciation and amortization | ¥317 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on retirement of non-current assets 155 Thousands of yen |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (no company names provided) / Excluded 0 companies (no company names provided) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Investors and analysts |
| Issued Shares at Period-End | 28,057,400 shares |
| Treasury Shares at Period-End | 3,191,062 treasury shares |
| Factors Behind Changes in Business Performance | The increase in Web production, system development and video production projects in the non-pharmaceutical EVC area, a large-scale streaming system project in the OTT area, and higher sales at consolidated subsidiaries contributed to revenue growth. The increase in expenses was contained through restrained hiring, cost reductions and more efficient organisational management. In the pharmaceutical EVC area, the lecture and seminar business fell below the previous year, mainly because major clients restrained budget spending. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Web production, system development and video production projects in the non-pharmaceutical EVC area progressed steadily, and a large-scale streaming system project was carried out in the OTT area. The increase in sales at consolidated subsidiaries also contributed, while the increase in expenses was contained through restrained hiring, cost reductions and more efficient organisational management. In the pharmaceutical EVC area, however, the lecture and seminar business as a whole fell below the previous year, mainly because major clients restrained budget spending.